Cortechs.ai | The importance of a 3D T1 sequence

The importance of a 3D T1 sequence

In this post, I explore why NeuroQuant processing uses a 3D T1 sagittal MRI sequence and that using other sequences will generate an unsupported MR sequence error message.

Previously, I reviewed how to ensure accurate NeuroQuant processing results, and my colleague discussed why contrast agents are not used to achieve quality segmentation with NeuroQuant, and examined why good alignment to atlas is necessary for accurate NeuroQuant output.

3D T1 sagittal MRIs are needed to obtain ideal brain morphometry for volume analysis. In order to achieve its high-quality segmentation results, NeuroQuant has been optimized for processing 3D T1 sagittal MRI acquisition sequence in 1.2, 1.5 and 3.0T scanners.

As a quality control feature, NeuroQuant contains a data filtering mechanism that provides verification of study scanning parameters prior to initiating processing. Ensuring proper processing preserves the accuracy of the segmentation results and therefore, the accuracy of the calculated brain volumes. To protect the accuracy of the results, NeuroQuant prevents analysis when sequences other than 3D T1 are sent for processing.

The unsupported sequences provided as examples below will generate an error message.

unsupported_seq.png

Another example that will generate an error message happens when the wrong series (or entire exam) is sent. When an entire exam is sent instead of just the required 3D T1 NeuroQuant scan, there can be a  delay in the return of NeuroQuant results, which will result in multiple error messages being sent back to the PACS.

More information about using and processing NeuroQuant can be found here.

More Resources

11/19/2025

Philips and Cortechs.ai extend partnership to advance quantitative neuroimaging and strengthen Philips’ leadership in precision diagnostics in neurology

The companies will integrate Cortechs.ai’s advanced AI-enabled neuroimaging analytics directly into Philips’ MR systems.

11/17/2025

Unlocking the Value of NeuroQuant Reports: Different Use Cases Across Clinical Practice

From neurodegeneration and demyelination to development, trauma, and seizures, NeuroQuant supports better decision‑making, communication, and patient care

11/17/2025

Case Study: Augmenting Prostate Imaging Programs with OnQ™ Prostate

Discover how Imaging Healthcare Specialists integrated OnQ™ Prostate to enhance lesion visibility, boost diagnostic confidence, and improve communication.

11/04/2025

NeuroQuant Dementia in Different Use Cases 

NeuroQuant transforms brain imaging into a measurable biomarker for neurodegeneration by combining volumetric data with clinical expertise.

10/29/2025

Enhancing Brain Tumor Treatment with RT STRUCT Images: The Promise of Automation

Automating the generation of RT STRUCT images with NeuroQuant Brain Tumor can streamline workflows and elevate the standard of care

10/15/2025

Sharper Screening, Smarter Biopsies: OnQ Prostate and the Next Step in Imaging

Read to learn how OnQ Prostate goes beyond existing solutions like DynaCAD and redefines biopsy precision
Scroll to Top